Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916370 · ClinicalTrials.gov registry record · Phase 3
SPIRIT PRIME Clinical Trial
A Phase 3 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
NCT00916370 is a Phase 3 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 525 participants.
The verdict
NCT00916370, a Phase 3 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel.
Interventions
- DEVICE Core size Xience Prime
- DEVICE Xience Prime Long Lesion (LL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00916370
The ClinicalTrials.gov registry entry for NCT00916370 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Core size Xience Prime is the first listed.
NCT00916370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00916370 about?
NCT00916370 is a clinical study titled "SPIRIT PRIME Clinical Trial". To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a ...
What is the current status of trial NCT00916370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2009-06. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00916370?
The interventions under investigation include: Core size Xience Prime (DEVICE), Xience Prime Long Lesion (LL) (DEVICE).
Who is sponsoring clinical trial NCT00916370?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.